January 2026 Research Update

Across the evidence, caplacizumab use during an acute immune thrombotic thrombocytopenic purpura (iTTP) episode generally lined up with faster control of the low-platelet problem and less intensive hospital treatment, and some reports suggested that starting earlier may add benefit. The strongest overall picture comes from a pooled analysis that included both randomized trials and real-world studies, while smaller reports help describe specific high-risk situations such as stroke. [1] [2]

In a systematic review and meta-analysis of 13 studies including 2,956 patients, caplacizumab was linked to fewer daily therapeutic plasma exchange sessions and quicker platelet count normalization. The same analysis also reported lower mortality, fewer iTTP exacerbations, and shorter hospital stays, and it noted that earlier initiation may provide additional benefit. [1]

A small case series described three people with thrombotic thrombocytopenic purpura who presented with acute ischemic stroke confirmed on brain MRI and had very low ADAMTS13 activity. All received plasma exchange and corticosteroids, with caplacizumab started at stroke onset in one case and added after initial treatment in two cases; all had blood count recovery and there were no reported adverse events or deaths. The authors noted that neurologic recovery could not be credited to caplacizumab alone because multiple treatments were used. [2]

For patients and caregivers, these studies mainly add context about what hospitals have reported when caplacizumab is used during an acute iTTP episode: outcomes related to platelets, plasma exchange needs, time in the hospital, and survival tended to move in a better direction in pooled research, and stroke cases have been described with blood recovery during combined treatment. What remains uncertain from these summaries is how much benefit comes from caplacizumab versus the other treatments given at the same time in individual patients, and how results vary across different health systems and situations.

Two observational cohorts highlighted that acute thrombotic thrombocytopenic purpura care still carries serious short-term risks and that longer-term problems (relapse or ongoing neurologic or psychiatric symptoms) can occur among survivors. In these real-world settings, rituximab use was repeatedly linked to better outcomes (survival in one cohort and fewer relapses in another), although these studies cannot prove cause and effect. [3] [4]

In a multicenter prospective cohort from Brazil (85 patients, 2018-2024), most patients received plasma exchange and corticosteroids, and over half received rituximab. In-hospital mortality was 15.3%, about a quarter of survivors later had an exacerbation or relapse, and 22.4% developed chronic neurologic or psychiatric sequelae; rituximab appeared protective against relapses in this cohort. The study also highlighted delays in diagnosis and outdated treatment practices as ongoing challenges in that setting. [4]

In a single-center retrospective study from China of 96 adults with first-episode immune TTP seen in the emergency department (2004-2024), overall mortality was 38.5% and relapse among survivors was 13.6%. Rituximab use increased over time and was associated with improved survival, and corticosteroid pulse therapy was reported as an independent predictor of better clinical response. The authors noted limits such as single-center design and missing ADAMTS13 and caplacizumab data in their dataset. [3]

For patients and caregivers, these studies mainly serve as real-world snapshots of how acute TTP has been treated in different hospitals and what outcomes were seen, including the possibility of relapse and longer-term neurologic or psychiatric effects in some survivors. The repeated link between rituximab use and better outcomes suggests an area of active attention in TTP care, but the evidence here comes from observational research where other differences between patients could also affect results. It also remains unclear how much differences in outcomes reflect access to specialized testing and timely care, which varied by setting in these reports.

Across these papers, the main message is that safety during plasma exchange in immune thrombotic thrombocytopenic purpura (immune TTP) depends on both the central line used for treatment and the properties of the plasma product used for replacement. One study described many complications during real-world care with central venous catheters, and another study (in the lab) tested a modified plasma product designed to lower pathogen risk and change clotting-related components. [5] [6]

In a single-center observational study of 33 acute immune TTP episodes requiring a central venous catheter for therapeutic plasma exchange, 91% of episodes had at least one complication and 64% had at least one major complication. Major events included catheter-related blood clots (5 venous thromboses) and infections (2 bloodstream infections and 1 local infection), and episodes with major catheter complications were linked to longer hospital stays. [5]

The same study reported procedure-related issues that may happen during plasma exchange, including allergic-type rashes needing treatment (16 episodes), low calcium needing treatment (8 episodes), and smaller numbers of low blood pressure or heart failure episodes. Minor bleeding at the catheter site was also reported (19 bleeds across 16 episodes), and catheter dysfunction sometimes required replacement. [5]

A separate laboratory study examined pathogen-reduced, cryoprecipitate-reduced plasma (PRPCR) as a potential replacement fluid for plasma exchange and compared it with pathogen-reduced plasma. PRPCR kept ADAMTS13 and antibodies (immunoglobulins) similar to the comparison plasma but had lower fibrinogen, factor VIII, and von Willebrand factor, and it showed reduced platelet sticking and clot formation in high-shear flow experiments. The authors noted these are lab results and not clinical trial outcomes. [6]

For patients and caregivers, this set of studies mainly provides context on two parts of plasma exchange care: complications related to the central line and how different plasma products might behave. The complication rates reported come from one center and may not match every hospital, but they highlight that infections, catheter-related clots, allergic reactions, and low calcium were all seen during acute immune TTP treatment. The replacement-plasma study is background research (not patient outcomes) and suggests a modified plasma could potentially preserve key immune TTP-related components like ADAMTS13 while reducing some clot-forming features, but whether this changes real-world safety or effectiveness remains uncertain without clinical trials. [5] [6]

Across these studies, relapse in thrombotic thrombocytopenic purpura (TTP) was not explained by a single test. Researchers reported signals from clinical features (like younger age and severe brain-related symptoms), differences between ancestry groups after rituximab, and newer biomarker approaches that look beyond standard ADAMTS13 activity alone. [7] [8] [9]

In a single-center retrospective study of 123 people with TTP, being age 30 years or younger and having severe neuropsychiatric symptoms were each linked to higher relapse risk, and a model using these factors had moderate discrimination (AUC 0.706). The same team also explored bone marrow proteins in 18 samples and highlighted TMEM109 as a relapse-associated marker, with lower TMEM109 levels in relapsed cases and high discrimination (AUC 0.929). [7]

In a large French prospective registry of 790 adults with immune-mediated TTP treated with rituximab, African ancestry was independently linked to shorter relapse-free survival after the first rituximab-treated episode. Time to recovery of ADAMTS13 activity to 20% or higher was similar between African and European ancestry groups (median 36-37 days). [8]

In a small retrospective study of 15 adults followed for a median of 7 years, ADAMTS13 activity returned to normal between relapses for everyone, but an "open" ADAMTS13 shape during remission was more common around relapse and was tied to faster relapse in people with higher relapse rates. When ADAMTS13 activity had normalized but remained in an open shape, time to relapse was shorter in the higher-relapse group (5 months vs 21 months). [9]

For patients and caregivers, these studies reinforce that remission monitoring may involve more than checking whether ADAMTS13 activity has returned to a safer range, because relapse can still occur even after activity normalizes. Some results (like ancestry differences after rituximab) come from a large real-world registry and may help explain why relapse risk can vary across groups, while other results (like ADAMTS13 shape and TMEM109 in bone marrow) are earlier-stage and need confirmation before they can be considered routine tools. [7] [8] [9]

Across these studies, remission after immune-mediated thrombotic thrombocytopenic purpura (iTTP) did not always mean a full return to pre-illness brain health or emotional well-being. Results pointed in the same direction: ongoing cognitive and mental health challenges can persist, and some brain changes may continue over time, although parts of brain blood vessel function may improve. [10] [11]

In a small 12-month follow-up study of 22 iTTP survivors, most people had brain scan abnormalities and all had signs of blood-brain barrier disruption soon after remission, which improved slightly by 12 months but did not normalize. Over the same year, brain scans showed continued brain volume loss and worsening measures of white matter integrity in areas linked to memory and verbal skills. Cognitive testing stayed below control levels, especially for memory and verbal tasks, suggesting that some brain injury may continue even after remission. [10]

In a survey study of 101 adults with iTTP in remission compared with 76 healthy controls, people with iTTP reported worse health-related quality of life across all measured areas and more symptoms of anxiety, depression, and post-traumatic stress. In this study, caplacizumab exposure during the acute phase was linked to a lower risk of severe anxiety, but overall quality-of-life scores did not differ between those who did and did not receive caplacizumab. Because the survey was cross-sectional and used screening questionnaires, it cannot show cause and effect or replace a clinical diagnosis. [11]

For patients and caregivers, these results support the idea that "feeling back to normal" can take longer than blood counts returning to normal, and that recovery may involve both thinking (especially memory and word-related tasks) and mental health. Right now, this evidence mainly helps explain why some people report persistent cognitive or emotional symptoms after iTTP, and it highlights uncertainty about how long these changes last and who is most affected. The imaging work is still based on a small group, and the mental health survey cannot prove why symptoms occur, so larger and longer studies are still needed. [10] [11]

Across these papers, kidney and pregnancy-related complications around thrombotic microangiopathy (a condition where small blood vessels can become blocked) looked uncommon but serious when they occur. The overall message is that kidney injury in immune-related thrombotic thrombocytopenic purpura (TTP) may not always be explained by TTP alone, and postpartum readmissions with thrombotic microangiopathy had much worse hospital outcomes than typical readmissions. Both studies also highlight uncertainty about causes, because different disorders can look similar and can overlap.

In a case series of 10 patients with immune-mediated TTP who underwent kidney biopsy, seven had other conditions including autoimmune diseases, infections, or malignant hypertension, and five had biopsy findings described as proliferative glomerulonephritis or malignant hypertension. [12] The authors suggested these biopsy results could mean overlap with other forms of kidney thrombotic microangiopathy and raised the possibility that the complement immune pathway might be involved, but genetic testing for complement-related variants was not done. [12]

In a US Nationwide Readmission Database study (2016-2021), postpartum readmission for pregnancy-associated thrombotic microangiopathy was very rare, with 41 cases among more than 11 million deliveries. [13] When it happened, these readmissions had a higher combined rate of death, blood clots, or major bleeding than non-thrombotic microangiopathy readmissions (26.8% vs 4.7%). [13]

The same postpartum study found longer hospital stays (median 8 vs 2 days) and higher hospital costs (median $117,532 vs $18,261) for thrombotic microangiopathy readmissions compared with other readmissions. [13] Therapeutic plasma exchange (a blood-filtering procedure sometimes used in TTP and related conditions) was started quickly during these readmissions, with a median time to first treatment of 1 day. [13]

For patients and caregivers, this group of studies mainly adds context about how complex kidney and pregnancy-related complications can be in and around TTP and related clotting-in-small-vessels conditions. The kidney biopsy report suggests that when severe sudden kidney injury happens in immune-related TTP, there may sometimes be another kidney problem present at the same time, which can make the situation harder to interpret. [12] The postpartum database study suggests that readmissions labeled as pregnancy-associated thrombotic microangiopathy are uncommon, but when they occur they are linked to higher in-hospital risks such as clots and bleeding; the study cannot explain exactly which specific underlying diagnosis each person had because it relied on hospital coding. [13]

Across these papers, a repeated pattern was that several different conditions can look like thrombotic thrombocytopenic purpura (TTP) at first, because they share the same emergency features: low platelets, red blood cell damage, and organ stress (especially kidneys and brain). The reports highlight that early bedside probability tools and careful testing can help clinicians separate TTP from other thrombotic microangiopathies, because the main driver can be different in different patients. [14]

One paper described several thrombotic microangiopathy cases and emphasized using French and PLASMIC scores at admission to estimate how likely TTP is, with the goal of not delaying initial care when the likelihood is high. This reflects the real-world challenge that confirmatory testing may not be immediately available, even though the decision-making is time-sensitive. [14]

Several single-patient reports showed how non-TTP triggers can produce a very similar picture. In a 41-year-old woman, a post-abortion infection was linked to atypical hemolytic uremic syndrome (aHUS), and therapeutic plasma exchange was followed by improved urine output and eventual stopping of dialysis; TTP was considered less likely because ADAMTS13 activity was reported as normal. [15]

Two other case reports highlighted different lookalikes and different responses. After snakebite, a 22-year-old man developed thrombotic microangiopathy with kidney injury and neurologic decline, and he gradually improved after five plasma exchange sessions plus intensive supportive care; the authors noted ADAMTS13 testing was not available and raised concern that earlier platelet transfusions may have worsened small-vessel clotting. [16]

In a 70-year-old woman with a malfunctioning artificial mitral valve, atypical HUS was diagnosed in the setting of complement overactivation (with elevated sC5b-9 despite normal C3/C4), and she improved rapidly after complement inhibition with eculizumab before valve repair; TTP was ruled out because her ADAMTS13 activity was 19%, mildly low but above the under-10% level typical of TTP. This case suggested valve dysfunction may act as a contributing factor rather than the only cause. [17]

In a man in his 60s with Capnocytophaga bloodstream infection from a dental source, the thrombotic microangiopathy initially resembled TTP but improved with antibiotics and source control without plasma exchange. The authors interpreted this as supporting an infection-related mechanism rather than primary TTP in that patient. [18]

For patients and caregivers, these papers mainly reinforce that a TTP-like emergency can have different underlying causes, including infection, pregnancy-related complications, toxins such as snake venom, or mechanical heart valve problems, and that the label matters because the most effective approach may differ case to case. The evidence here is mostly case reports and a small case series, so it describes what happened in a few individuals rather than establishing how often each cause occurs or which strategy is best overall. Uncertainty remains when key tests (such as ADAMTS13 activity or specialized complement markers) are unavailable or hard to interpret, which is part of why clinicians may use probability tools and repeated reassessment in real-world settings. [14]

Across three single-patient reports, thrombotic thrombocytopenic purpura (TTP) occurred at the same time as other major illnesses, and the overall message was mixed: some people recovered fully, while others did not despite intensive care. These reports also highlighted that similar-looking clotting problems can have different causes in settings like HIV, so tests that measure ADAMTS13 (a blood protein involved in clotting) were central to clarifying immune-mediated TTP. Because all evidence here comes from case reports, it is unclear how often these situations happen or how generalizable the outcomes are. [19] [20] [21]

In one report, a woman was found to have previously undiagnosed HIV and had immune-mediated (acquired) TTP with very low ADAMTS13 activity and antibodies against ADAMTS13; she reached remission after plasma exchange, caplacizumab, steroids, and starting antiretroviral therapy for HIV. Her ADAMTS13 activity later returned to normal range and stayed stable at 9 months, even though she experienced several serious infections during care. The authors also stressed that not all HIV-related thrombotic microangiopathy (small-vessel clotting syndromes) is the same as immune-mediated TTP, which matters because the underlying cause can affect how clinicians interpret remission. [19]

In another report, a woman with active systemic lupus erythematosus developed immune-mediated TTP about 10 weeks after starting anifrolumab, with neurological symptoms and low ADAMTS13 activity. She improved with plasma exchange, corticosteroids, caplacizumab, and rituximab, and her blood counts and neurological symptoms recovered; there was no recurrence reported at 2 months. The authors noted that a cause-and-effect link to anifrolumab cannot be proven from one case. [20]

A third report described a man whose immune-mediated TTP was the first sign of acute myeloblastic leukemia (AML). Despite plasma exchange, corticosteroids, rituximab, and leukemia induction chemotherapy, improvement was only temporary and he died about 5 weeks after diagnosis, with complications including pneumonia leading to septic shock and brain bleeding after seizures. This case illustrates that when TTP occurs with an aggressive blood cancer and severe complications, the course can be difficult even with multiple therapies. [21]

For patients and caregivers, these reports mainly serve as background context that TTP can sometimes occur together with other serious illnesses (such as HIV infection, lupus flares, or leukemia), and that the combination can affect the overall clinical course. They also underline why doctors often look for contributing conditions and use ADAMTS13 testing to help distinguish immune-mediated TTP from other similar clotting disorders, especially in settings like HIV. What remains uncertain is how common each scenario is, whether specific triggers (like anifrolumab) truly increase risk, and how much the underlying illness versus TTP itself drives outcomes in larger groups of people.